COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 1 FDA record to the applicant name Ibsa Institut Biochimique SA. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jul 24, 2026 to Jul 24, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code MOZ appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P110005, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: Via Al Ponte 13, Ch-6903, Lugano Ticino, 6903. Recorded on P110005/S015, decision dated Jul 24, 2026.
Device categories in this collection
Acid, Hyaluronic, Intraarticular.
Changes described in PMA records
FDA’s recorded scope: Approved for the addition of a new dispensing area, Room A107, for the sampling and weighing of raw materials used in the manufacture of GELSYN-3 (sodium hyaluronate 0.84%) at the IBSA Farmaceutici Italia Srl facility in San Grato-Lodi, Italy, under the same FEI as the currently approved dispensing area
Jul 24, 2026 · 30-Day NoticeSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.